Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » MBHS

 - UBBFriend: Email this page to someone!    
Author Topic: MBHS
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Put MBHS on watch. The companys latest update was about what stage there SkinScan 650 is at and how physicians can do this test right in there offices. Were going to see some big things from this company in the near future, Stock has been showing some good volume and decent gains these past couple of days. Today hasnt done much but I think its ready for some big news soon!! I think were at a good entry price here @.25 We have seen thisat .38 a few weeks ago and when news hits the wire I think we will be trading at that level again or even higher. I think were at a good entry price here. Here is the latest news from 7/16 there is also a link to the webite in the news. Check it out..



TEL AVIV, Israel, July 16, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update. The Company believes in the importance of regular communication and timely information delivered to investors. To this end, MBHS is committed to share with its stockholders regular updates on its progress.



MBHS, through its wholly owned subsidiary Skin Cancer Scanning ltd. ("SCS") is pioneering the development and commercialization of a revolutionary and proprietary diagnostic device for the early detection and diagnosis of skin cancer. Our product, an advanced stage prototype, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers.



SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.



To date, we have successfully conducted two stages of clinical trials. The results from 128 scanned nevi demonstrated 92.4% accuracy in diagnosing non-melanoma skin cancer. These results are significantly higher than the 75% accuracy achieved by an experienced physician and 65% accuracy achieved by a general practitioner.



For more information on SCS, visit the company's new website at www.scs-med.com

Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share